MEDomics LLC Announces Private Placement Offering

MEDomics LLC Announces Private Placement Offering
New MitoDx™ Test for Mitochondrial Diseases is the First to Tap Multi-Billion Dollar Potential Market.
to online conversations, before leaping into any social media platform. Approximately 70% of the time spent with social media should be spent listening. In general, spend twice as much time listening as responding.
Los Angeles, CA November 20, 2009 -- MEDomics, LLC announces a Private Placement offering of shares.
MEDomics (www.medomics.com) provides DNA diagnostics to enable personalized medicine in the genomic era. MEDomics is the first CLIA approved laboratory focused on the application of revolutionary NextGen sequencing technology to molecular diagnosis. The Company’s “2020 Vision” is a world in which the main focus of medicine has evolved from treating the sick patient, to knowledge based risk management, to delay or prevent disease.
MEDomics integrates laboratory expertise in NextGen sequencing with expertise in bioinformatics and clinical interpretation of the results. MEDomics has the first mover advantage and a fully functioning and tested team that has an unrivaled a track record of bringing novel molecular diagnostics to market. MEDomics is applying NextGen sequencing to the unmet need for better diagnostics for mitochondrial diseases.
Mitochondria are the powerhouses of the cell. Mitochondrial diseases are much more common than originally thought, occurring in about 1 in 500 people. In children, mitochondrial diseases are as common as all childhood cancers combined. The symptoms of mitochondrial diseases are extremely diverse, depending on which tissues are most energy compromised. The brain, muscles, eyes, the gastrointestinal track, and the heart are most commonly affected. Patients often carry a descriptive diagnosis such as: epilepsy, migraine headache, chronic fatigue, chronic pain syndrome, cyclic vomiting syndrome, mental retardation, or autism, etc. The diagnosis of mitochondrial diseases can save lives and enable effective treatment, such as increasing available energy or decreasing energy stress.
MitoDx was released in July 2009. MitoDx has substantial media coverage including:
i) Pasadena Star News:
http://www.medomics.com/sites/default/files/docs/news/Pasadena Star News.pdf
ii) Los Angeles CBS News: http://www.medomics.com/sites/default/files/docs/news/MEDomics 16Jul09.wmv and
iii) Hawaii CBS News:
http://www.medomics.com/sites/default/files/docs/news/110509 MEDomics TV interview in Hawaii Sun 10-25-09 KHON 6pm.wmv

Richard Boles, MD, the Director of the Mitochondrial and Metabolic Disorders Clinic at Children’s Hospital Los Angeles, is a distinguished clinical consultant for MEDomics on mitochondrial diseases.
Dr. Sommer says that, “To my knowledge, the MEDomics team is unique. We provide excellent wet bench expertise, proprietary software and knowledge database, extensive connections with clinicians and scientist in the mitochondrial disease community and unparalleled expertise in clinical interpretation. We also nurture and grow our trade secrets and intellectual property engines”
Capital from the Private Placement will: i) expedite the release of a companion diagnostic test enabling a single source, high specificity blood test for all mitochondrial diseases; and ii) dramatically accelerate marketing, thereby consolidating MEDomics’ market leadership to address a large unmet need for mitochondrial disease diagnostics. MEDomics is uniquely positioned to be the dominant testing lab for mitochondrial diseases. The ultra-rapid progress in the field suggests that a $1 investment today is equivalent to a $10 investment in 2.5 years.
MEDomics, LLC
426 N. San Gabriel Ave.
Azusa, CA 91702
626.804.3645
www.medomics.com
info (at) medomics (dot) com